Drug Profile
NI 203
Alternative Names: NI-203Latest Information Update: 07 Jun 2021
Price :
$50
*
At a glance
- Originator Neurimmune Therapeutics
- Class Antihyperglycaemics; Monoclonal antibodies
- Mechanism of Action Islet amyloid polypeptide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Type 2 diabetes mellitus
Highest Development Phases
- Preclinical Type 2 diabetes mellitus
Most Recent Events
- 07 Jun 2021 NI 203 is still in preclinical development for Type-2-diabetes-mellitus in Switzerland (Parenteral) (Neurimmune Therapeutics pipeline June 2021)
- 28 May 2021 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Switzerland
- 26 Apr 2017 NI 203 is available for licensing as of 26 Apr 2017. http://www.neurimmune.com/company/about-neurimmune.html